Table 2.

Stage I and II meta-analysis of univariate Cox regression analysis results for the four associations in stage I and II

ER-positive patients receiving endocrine treatment
SNPChr:positionaMAFbHEBCS GWS HR (95% CI)HEBCS GWS PPOSH GWS HR (95% CI)POSH GWS PPOSH val. HR (95% CI)POSH val. PSuccess-A HR (95% CI)Success-A PMeta-analysis HR (95% CI)Meta-analysis PLocation
rs811330819:524453860.1521.72 (1.08–2.72)0.0222.17 (1.37–3.45)9.81 × 10−41.45 (1.04–2.02)0.0301.72 (1.11–2.68)0.0151.69 (1.37–2.07)6.34 × 10−7ZNF613
rs40828434:71090830.1640,40 (0.23–0.67)6.50 × 10−40,36 (0.15–0.82)0.0151,07 (0.75–1.51)0,4840.72 (0.55–0.95)2.18 × 10−2GRPEL1 | SORCS2
rs476741312:1169510690.1782,06 (1.41–3.01)1.90 × 10−41,67 (1.08–2.57)0.0211,13 (0.82–1.56)0,3281.07 (0.73–1.58)0.7211.39 (1.15–1.67)5.86 × 10−4MED13L | LINC00173
rs1108509819:47845530.3071,76 (1.25–2.47)0.0011,61 (1.11–2.33)0.0120,92 (0.69–1.22)0,2420.83 (0.59–1.17)0.2771.16 (0.99–1.37)7.02 × 10−2MIR7–3HG | FEM1A
ER-positive patients not receiving endocrine treatment
SNPChr:positionaMAFbHEBCS GWS HR (95% CI)HEBCS GWS PPOSH GWS HR (95% CI)POSH GWS PPOSH val. HR (95% CI)POSH val. PSuccess-A HR (95% CI)Success-A PMeta-analysis HR (95% CI)Meta-analysis PLocation
rs811330819:524453860.1520.66 (0.40–1.07)0.093ZNF613
rs40828434:71090830.1641.15 (0.78–1.700,486GRPEL1 | SORCS2
rs476741312:1169510690.1780.91 (0.56–1.48)0,712MED13L | LINC00173
rs1108509819:47845530.3071.01 (0.70–1.46)0,963MIR7–3HG | FEM1A
ER-negative patients
SNPChr:positionaMAFbHEBCS GWS HR (95% CI)HEBCS GWS PPOSH GWS HR (95% CI)POSH GWS PPOSH val. HR (95% CI)POSH val. PSuccess-A HR (95% CI)Success-A PMeta-analysis HR (95% CI)Meta-analysis PLocation
rs811330819:524453860.1520.65 (0.42–1.03)0.0640.71 (0.46–1.09)0.1210.93 (0.46–1.88)0.8420.49 (0.26–0.93)0.0290.71 (0.56–0.91)6.00 × 10−3ZNF613
rs40828434:71090830.1641,06 (0.73–1.52)0.7651,00 (0.73–1.37)0.9780,80 (0.38–1.67)0.3461.00 (0.80–1.26)0.984GRPEL1 | SORCS2
rs476741312:1169510690.1781,01 (0.64–1.61)0.9581,04 (0.76–1.42)0.8061,44 (0.80–2.580.1480.98 (0.72–1.34)0.6521.09 (0.89–1.33)0.400MED13L | LINC00173
rs1108509819:47845530.3070,88 (0.64–1.21)0.4281,00 (0.77–1.29)0.9780,91 (0.56–1.47)0.4601.09 (0.75–1.59)0.8960.95 (0.81–1.12)0.544MIR7-3HG | FEM1A

NOTE: The table presents per study as well as the meta-analysis results in ER-positive patients receiving endocrine treatment, ER-positive patients not receiving endocrine treatment, and ER-negative patients. The per study results in ER-positive patients not receiving endocrine treatment are only presented for HEBCS, because very few ER-positive patients did not receive endocrine treatment in POSH GWS, POSH validation, and SUCCESS-A. For SNPs rs4082843, there was no exact SNP match or a tag SNP with r2 > 0.8 available in SUCCESS-A data.

  • aAccording to the human genome build 36.

  • bMAF in Caucasian of European descent.